Lester Murray Antman dba SimplyRich Has $1.30 Million Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Lester Murray Antman dba SimplyRich lifted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 205.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 24,315 shares of the company’s stock after acquiring an additional 16,351 shares during the quarter. Lester Murray Antman dba SimplyRich’s holdings in Janux Therapeutics were worth $1,301,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Plato Investment Management Ltd boosted its stake in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock valued at $54,000 after buying an additional 187 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Janux Therapeutics during the 4th quarter worth about $139,000. AQR Capital Management LLC bought a new stake in shares of Janux Therapeutics in the 2nd quarter valued at approximately $215,000. Finally, Chicago Capital LLC acquired a new position in Janux Therapeutics in the fourth quarter worth approximately $230,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $36.11 on Wednesday. The business has a 50 day simple moving average of $50.54 and a 200 day simple moving average of $48.23. Janux Therapeutics, Inc. has a one year low of $7.81 and a one year high of $71.71. The company has a market capitalization of $1.90 billion, a PE ratio of -30.86 and a beta of 3.16.

Insider Activity

In other news, CEO David Alan Campbell sold 25,000 shares of Janux Therapeutics stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00. Following the completion of the transaction, the chief executive officer now owns 257,054 shares in the company, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Andrew Hollman Meyer sold 13,334 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now owns 82,139 shares in the company, valued at approximately $4,507,788.32. This trade represents a 13.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 86,668 shares of company stock worth $4,872,515. Corporate insiders own 29.40% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on JANX. BTIG Research lifted their price objective on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Scotiabank raised their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 4th. Leerink Partners upped their target price on shares of Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Finally, UBS Group assumed coverage on Janux Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $69.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $89.90.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.